Trial Profile
A Long-term, Open-label Study Evaluating the Safety and Tolerability of [Vortioxetine] Lu AA21004 in Patients With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2023
Price :
$35
*
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 01 Apr 2023 Results of pooled analysis from NCT00761306 and NCT01323478 assessing safety and efficacy of vortioxetine in the management of major depressive disorder published in the Current Medical Research and Opinion
- 22 Feb 2017 New trial record